innaRx develops best-in-class oral modulators in innate immunity for I&I patients
Our Pipeline
Lead indication Paroxysmal Nocturnal Hemoglobinuria: Phase 2 Study in C5 naïve PNH patients showed robust efficacy and safety profile consistent with mechanism of action.
​
Active US FDA IND; targeting FDA EOP-2 meeting Q4/2024.
Our Science
Pipeline-in-a-Product Opportunities for innaRxÂ
Complement dysregulation is linked to over 150 indications beyond hematology, but only a subset has demonstrated proof of concept (POC) in humans.
Approximately more than 100 indications have evidence solely from animal or cell studies. ~30 indications have successful POC for complement inhibition
~15 indications are in clinical development with a successful clinical proof-of-concept.
Source: Citeline’s PharmaProjects; Clinicaltrials.gov, Karin et.al., CKJ (2013); Horiuchi T et al., Inflammation and Regeneration (2016); Company websites
Our Approach
Our oral approach for complement modulation offers an alternative for treating complex and rare immunological disorders with established proof-of-concept in the clinical studies. Through systemic complement modulation while enhancing tissue-specific concentrations in the bone marrow, kidney, liver, and thyroid, we improved patient compliance and broadened the therapeutic potential of complement inhibition.
